FDA Delays Decision on Eli Lilly's Alzheimer's Drug Donanemab
TL;DR Summary
The US regulator has postponed its decision on Eli Lilly's experimental Alzheimer's drug, donanemab, citing the need for more time to review additional data. The drug has shown promise in slowing the progression of the disease, and the delay in the decision is seen as a setback for the company's efforts to bring a new treatment to market.
- US regulator delays decision on Eli Lilly's Alzheimer's drug donanemab Financial Times
- U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of Donanemab | Eli Lilly and Company Investors | Eli Lilly and Company
- F.D.A. Delays Action on Closely Watched Alzheimer's Drug The New York Times
- Eli Lilly's donanemab Alzheimer's drug delayed by FDA USA TODAY
- Eli Lilly hits another Alzheimer's hurdle. But obesity, diabetes GLP-1s strong CNBC
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
0 min
vs 1 min read
Condensed
62%
153 → 58 words
Want the full story? Read the original article
Read on Financial Times